Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis
Targeted Oncology · 2025-11 · 20 (6) · 1015-1022
DOI: 10.1007/s11523-025-01180-2 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Targeted Oncology, online erschienen am 27.10.2025. Verfasst von Zaid Muhanna und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, Protein Kinase Inhibitors, Cardiotoxicity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard first-line therapy for EGFR-mutant non-small cell lung cancer (NSCLC). Emerging evidence suggests that it may be associated with increased cardiotoxicity; however, current evidence is conflicting, and a small sample size and a lack of direct comparisons with other EGFR-TKIs limit existing studies. OBJECTIVE: We aim to examine the incidence of cardiovascular toxicity with osimertinib compared with other EGFR-TKIs in a real-world setting. PATIENTS AND METHODS: A retrospective cohort study was conducted via the Trinetx global federated health research platform to compare the incidence of cardiotoxicity between osimertinib and other EGFR-TKIs over a 5-year follow-up. Patients were matched using 1:1 propensity score matching (PSM). Outcomes included cardiomyopathies, arrhythmias, ischemic heart disease (IHD), and heart failure (HF), assessed using ICD-10 codes. RESULTS: Following PSM, each arm consisted of 7331 patients; the arms were well balanced. Osimertinib was associated with increased risk of cardiomyopathy (2.8% vs 0.8%; HR: 3.143 [95% CI 2.342-4.218]), IHD (8.7% vs 5.5%; HR: 1.432 [95% CI 1.248-1.643]), and HF (6.2% vs 4%; HR: 1.41 [95% CI 1.210-1.644]). A similar incidence of arrhythmia was observed (9% vs 8.5%; HR: 0.938 [95% CI 0.831-1.059]); however, it increased after 3 years. Comparisons with individual EGFR-TKIs showed varying results. CONCLUSION: In this large, real-world study, osimertinib was associated with elevated cardiotoxicity risk. These findings underscore the need for serial monitoring of patients receiving osimertinib and for future studies comparing cardioprotective drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Jordan, Amman, Jordan.
- Roswell Park Cancer Center, Elm & Carlton Streets, Buffalo, NY, 14263, USA. muhammadawidi@gmail.com.
Zitieren
APA
Muhanna, Z., Al Zyoud, M., Issa, A., & Awidi, M. (2025). Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis. Targeted Oncology, 20(6), 1015-1022. https://doi.org/10.1007/s11523-025-01180-2
Vancouver
Muhanna Z, Al Zyoud M, Issa A, Awidi M. Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis. Targeted Oncology. 2025;20(6):1015-1022. doi:10.1007/s11523-025-01180-2
BibTeX
@article{Muhanna2025,
author = {Muhanna, Zaid and Al Zyoud, Muntaser and Issa, Ahmad and Awidi, Muhammad},
title = {Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis},
journal = {Targeted Oncology},
year = {2025},
volume = {20},
number = {6},
pages = {1015--1022},
doi = {10.1007/s11523-025-01180-2}
}
EUVIMED